Ksenija Schirduan

Title: Ksenija Schirduan: Innovator in Inflammatory Disorder Treatments

Introduction

Ksenija Schirduan is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of medical science, particularly in the treatment of inflammatory disorders. Her innovative approach has garnered attention and recognition in the scientific community.

Latest Patents

Ksenija holds a patent for an "Approach for treating inflammatory disorders." This invention focuses on a novel method that targets ROR gamma t mRNA. The patent describes oligonucleotides comprising 10 to 22 modified or unmodified nucleotides that are complementary to specific regions of the RORC, transcript variant 2 mRNA (RORC2). This mRNA codes for the ROR gamma t protein, which plays a crucial role in inflammatory responses.

Career Highlights

Throughout her career, Ksenija has worked with notable companies in the pharmaceutical industry. She has been associated with Secama Pharmaceuticals GmbH & Co. KG and Secarna Pharmaceuticals GmbH & Co. KG. Her work in these organizations has contributed to advancements in therapeutic solutions for various diseases.

Collaborations

Ksenija has collaborated with esteemed colleagues, including Sven Michel and Frank Jaschinski. These partnerships have enhanced her research and development efforts, leading to innovative solutions in her field.

Conclusion

Ksenija Schirduan is a trailblazer in the treatment of inflammatory disorders, with a focus on targeting specific mRNA pathways. Her contributions to medical science through her patent and collaborations highlight her commitment to advancing healthcare solutions.